Evidence map›Paper›PMID 42163934›Full record

ArticleLancet regional health. Americas2026

Rapid hepatitis C test and treat with peer support at opioid treatment programs (RAPID HCV): a hybrid effectiveness-implementation type 1 randomized control trial.

Oluwaseun Falade-Nwulia, Jennifer C Price, Jordan J Feld, Ellen Eaton, Ricardo A Franco, Brittany Barnaba, Diane Brown, Sarah Hussain, Tarfa Verinumbe, Catherine Wren and 9 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Lancet regional health. Americas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04677153 (Rapid HCV Test and Treat to Increase HCV Treatment Uptake Among People Who Use Drugs), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04677153 nacompletednot on this map

Rapid HCV Test and Treat to Increase HCV Treatment Uptake Among People Who Use Drugs

TypeinterventionalSponsorJohns Hopkins UniversityRan2021 to 2024Enrolled198ConditionsHepatitis C Virus Infection, Response to Therapy ofArmsTest and treat plus peer mentors, Usual care
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Oluwaseun Falade-NwuliaJohns Hopkins University School of Medicine, 600 N Wolfe St., Baltimore, MD, 21287, USA.
Jennifer C PriceSchool of Medicine, University of California San Francisco, Medical Sciences Building, 513 Parnassus Ave, San Francisco, Suite S-224, CA, 94143, USA.
Jordan J FeldToronto Centre for Liver Disease, University Health Network, University of Toronto, 1664 Dufferin St, Toronto, Ontario, M6H 3M1, Canada.
Ellen EatonDivision of Infectious Diseases, University of Alabama at Birmingham, 1900 University Boulevard, THT 229, Birmingham, AL, 35294, USA.
Ricardo A FrancoDivision of Infectious Diseases, University of Alabama at Birmingham, 1900 University Boulevard, THT 229, Birmingham, AL, 35294, USA.
Brittany BarnabaJohns Hopkins University School of Medicine, 600 N Wolfe St., Baltimore, MD, 21287, USA.
Diane BrownJohns Hopkins University School of Medicine, 600 N Wolfe St., Baltimore, MD, 21287, USA.
Sarah HussainJohns Hopkins University School of Medicine, 600 N Wolfe St., Baltimore, MD, 21287, USA.
Tarfa VerinumbeJohns Hopkins University School of Medicine, 600 N Wolfe St., Baltimore, MD, 21287, USA.
Catherine WrenJohns Hopkins University School of Medicine, 600 N Wolfe St., Baltimore, MD, 21287, USA.
Hamidreza Karimi-SariJohns Hopkins University School of Medicine, 600 N Wolfe St., Baltimore, MD, 21287, USA.
Kyoko HiroseSchool of Medicine, University of California San Francisco, Medical Sciences Building, 513 Parnassus Ave, San Francisco, Suite S-224, CA, 94143, USA.
Chris CavacuitiTrue North Medical Centre Toronto, 24 Dalhousie St, Toronto, Ontario, M5B 2A5, Canada.
Stephen T O'rearDivision of Infectious Diseases, University of Alabama at Birmingham, 1900 University Boulevard, THT 229, Birmingham, AL, 35294, USA.
Camelia CapraruToronto Centre for Liver Disease, University Health Network, University of Toronto, 1664 Dufferin St, Toronto, Ontario, M6H 3M1, Canada.
Karin TobinJohns Hopkins Bloomberg School of Public Health, 615 N Wolfe St. Baltimore, MD, 21205, USA.
Dhananjay VaidyaJohns Hopkins University School of Medicine, 600 N Wolfe St., Baltimore, MD, 21287, USA.
Sheree SchwartzJohns Hopkins Bloomberg School of Public Health, 615 N Wolfe St. Baltimore, MD, 21205, USA.
Mark SulkowskiJohns Hopkins University School of Medicine, 600 N Wolfe St., Baltimore, MD, 21287, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: People who use drugs (PWUD) face persistent barriers to hepatitis C virus (HCV) treatment, threatening HCV elimination goals. Integrating HCV testing and treatment into opioid treatment programs (OTPs) may increase access and uptake. We evaluated the effectiveness and implementation outcomes of an onsite HCV test and treat model delivered within OTPs. Methods: RAPID HCV was a multicenter, open label randomized controlled trial conducted at five OTPs in the United States and Canada. PWUD with a reactive antibody test were randomized (1:1) to onsite OTP-delivered HCV test and treat with peer support (RAPID HCV) or referral to offsite specialist care. Randomization was computer generated with concealed allocation. Following randomization, participants underwent clinical eligibility assessment for glecaprevir/pibrentasvir. The primary outcome was HCV treatment initiation within 12 weeks among treatment eligible participants (modified intention-to-treat [mITT]). The trial is registered at clinicaltrials.gov (NCT04677153). Findings: Between August 2021, and November 2023, 182 participants were randomized; 58 were ineligible for treatment and two were administratively excluded, yielding 122 in the mITT population. Median age was 49 years (IQR 38-58), 73 (60%) were male, and 85 (70%) had an illicit substance detected in urine at baseline. Treatment initiation occurred in 59 of 66 (89% [95% Confidence Interval 79-95]) RAPID HCV participants compared with 12 of 56 (21% [95% CI 13-34]) referred participants (p < 0.001). No serious adverse events related to study procedures or HCV treatment were observed. Interpretation: Onsite HCV test and treat with peer support delivered by OTP staff significantly increased HCV treatment initiation compared with offsite referral. Integrating HCV care into OTPs is an effective strategy to advance HCV elimination among PWUD. Funding: AbbVie.

Indexed as

Hepatitis COpioid treatment programPeople who use drugsTreatment

Identifiers

PMID42163934
PMCPMC13184505

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.